Navigation Links
Warner Chilcott Announces Secondary Equity Offering
Date:11/13/2009

rtainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and our Current Re
'/>"/>
SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
4. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
5. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
6. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Milestone Scientific Announces Third Quarter 2009 Results
9. EF Johnson Technologies Announces Third Quarter Results
10. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
11. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  Luminex Corporation (NASDAQ: ... the Morgan Stanley Global Healthcare Conference to be held ... Hotel in New York City . ... a.m. Eastern time on Friday, September 18, 2015.  The ... Luminex Corporation,s website at http://www.luminexcorp.com . Simply log on ...
(Date:9/4/2015)... , September 4, 2015 ... by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by ... and by Product - Global Forecast to 2020", published ... reach USD 2.5 Billion by 2020, growing at a ... to 2020. Browse 139 Tables and ...
(Date:9/4/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Rodman & Renshaw 17 th Annual Global Investment ... New York City .  Dr. Michael Berelowitz ... on September 9, 2015. Presentation Details: ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... UPI ), a medical device company ... to treat voiding dysfunctions, today announced that Noridian ... both regional Medicare carriers, now cover percutaneous, posterior ... Neuromodulation System for the treatment of the symptoms ...
... was voted the most powerful person in healthcare by readers ... business news magazine. It,s the second consecutive year Obama topped ... in Healthcare. "The passage of national healthcare reform ... Modern Healthcare Editor David Burda. "The Patient Protection ...
Cached Medicine Technology:Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 2Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 3Obama Named the Most Powerful Person in Healthcare for Second Consecutive Year 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and ... rules constantly evolving in the consumer goods industry, it can be difficult for ...
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco cosmetic dentist ... CEREC is a newer method for creating restorations through innovative imaging equipment and ... the need for multiple appointments, CEREC produces restorations with total precision for a ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... Seattle, Washington (PRWEB) , ... September 04, 2015 ... ... the design and development of its first neighborhood created specifically for adults with ... located in the Phoenix Metro area and feature 30 cottage or “pocket” homes. ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out ... role with the Vatican and society is. Yisrayl also provides the meaning of his own ...
Breaking Medicine News(10 mins):Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... ... The objective of the PACT program is to continue ... damaged/diseased tissues, organs, and biologic systems, and targeted treatments for serious ... will support translational research in novel cell therapies, to advance the ...
... ... Cycle Management Technology , ... March 3, 2010 -- References-Online, pioneer and leader in the customer reference management ... brand identity shift reflects the expanded suite of sales enablement solutions now offered ...
... , ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... brain tumours could soon be significantly reduced thanks ... University of Liverpool with the Nuclear Physics Group ... Facilities Council (STFC) at Daresbury Laboratory. Project ... SPECT (single photon emission computed tomography) imaging that ...
Cached Medicine News:Health News:NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT) 2Health News:NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT) 3Health News:Embodying an Evolving Solution Set, References-Online is Now RO|Innovation 2Health News:Embodying an Evolving Solution Set, References-Online is Now RO|Innovation 3Health News:Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership 2Health News:Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership 3Health News:Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership 4Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 2Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 4Health News:Marketech Celebrates 25 Years of Service 2Health News:Marketech Celebrates 25 Years of Service 3Health News:Marketech Celebrates 25 Years of Service 4Health News:Marketech Celebrates 25 Years of Service 5Health News:Nuclear physics promises earlier detection of brain tumors with just 1 scan 2Health News:Nuclear physics promises earlier detection of brain tumors with just 1 scan 3
... The ImmunoWELL Mumps IgG ... for the qualitative detection of ... results are used as an ... infection. Immune status may be ...
... is a qualitative enzyme immunoassay (EIA) ... virus capsid antigen (EBV-VCA), Epstein-Barr early ... Toxoplasma. When used in conjunction with ... in the serodiagnosis of infectious (EBV) ...
... The ImmunoWELL VCA IgG Test is an ... antibody to Epstein-Barr Virus viral capsid antigen (VCA) ... is used in conjunction with other testing such ... and EBV early antigen tests and/or heterophile tests, ...
... The ImmunoDOT Borrelia (Lyme) test ... dot-blot test for the qualitative ... specific (anti-P39) and related Borrelia ... IgA) are detected in serum ...
Medicine Products: